Bevacizumab: Not as good with more adverse reactions? Response

Clinical and Experimental Ophthalmology

Volumn 39, Issue 7, 2011, Pages 718-720

  Martin, Daniel F ^a   Maguire, Maureen G ^b   Fine, Stuart L ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE ANGIOGRAPHY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LETTER; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; STROKE; TREATMENT RESPONSE; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MACULAR DEGENERATION; MALE;

EID: 80053515840     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02703.x     Document Type: Letter

References (2)

1. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
2. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.